MedTrace Logo

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

NCT00286468 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2012-02-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with a sulfonylurea in adults with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

Alogliptin and glyburide

Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.

DRUG

Alogliptin and glyburide

Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.

DRUG

Glyburide

Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.

Sponsors & Collaborators

Principal Investigators

  • VP Biological Sciences · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Chile
  • Dominican Republic
  • Guatemala
  • India
  • Mexico
  • Netherlands
  • New Zealand
  • Peru
  • Poland
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00286468 on ClinicalTrials.gov